Off-The-Shelf Vaccines designed around what the immune system actually sees
Right Targets
Measured, not predicted
Our Precision Immunomics™ discovery pipeline integrates
state-of-the art immunopeptidomcs, transcriptomoics and genomics, with AI/ML trained on data from real patient samples, to produce a best-in-class repertoire of shared, tumour-specific antigens.
We detect antigens from coding and ‘dark’ regions of the genome without bias, allowing us to select the best possible targets, regardless of the source. Shortlisted targets undergo rigorous biological validation to allow us to design de-risked, off-the-shelf vaccines, cancer type by cancer type.
Everything we see is a real target.
Using immunopeptidomics, we directly read what tumours present to the immune system.
presentation
Most mutations are never processed, presented, or recognised by T cells so relying on prediction restricts the proportion of identified antigens that are therapeutically relevant.
Everything we see is a real target.
Using immunopeptidomics, wedirectly read what tumours present to the immune system.
Most mutations are never processed, presented, or recognised by T cells so relying on prediction restricts the proportion of identified antigens that are therapeutically relevant.
Right Vectors
Strong, durable T cell responses
from a single dose
